摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-cyano-1-cyclohexyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine | 1156500-43-4

中文名称
——
中文别名
——
英文名称
4-cyano-1-cyclohexyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine
英文别名
9-cyclohexyl-2-methoxy-7-methylimidazo[1,5-a]pyrido[3,2-e]pyrazine-6-carbonitrile;4-Cyano-1-cyclohexyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido-[3,2-e]pyrazine;3-cyclohexyl-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene-7-carbonitrile
4-cyano-1-cyclohexyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine化学式
CAS
1156500-43-4
化学式
C18H19N5O
mdl
——
分子量
321.382
InChiKey
IDBPPELBLKXMMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    24
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    76.1
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    potassium cyanide7-Chloro-3-cyclohexyl-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene 在 ethoxycarbonyldifluoromethyl magnesia chloride 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 15.0h, 以74%的产率得到4-cyano-1-cyclohexyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine
    参考文献:
    名称:
    Discovery of Imidazo[1,5-a]pyrido[3,2-e]pyrazines as a New Class of Phosphodiesterase 10A Inhibitiors
    摘要:
    Novel imidazo[1,5-a]pyrido[3,2-e]pyrazines have been synthesized and characterized as both potent and selective phosphodiesterase 10A (PDE10A) inhibitors. For in vitro characterization, inhibition of PDE10A mediated cAMP hydrolysis was used and a QSAR model was established to analyze substitution effects. The outcome of this analysis was complemented by the crystal structure of PDE10A in complex with compound 49. Qualitatively new interactions between inhibitor and binding site were found, contrasting with previously published crystal structures of papaverine-like inhibitors. In accordance with the known antipsychotic potential of PDE10A inhibitors, MK-801 induced stereotypy and hyperactivity in rats were reversed by selected compounds. Thus, a promising compound class has been identified for the treatment of schizophrenia that could circumvent side effects connected with current therapies.
    DOI:
    10.1021/jm1002793
点击查看最新优质反应信息

文献信息

  • Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
    申请人:Malamas Michael S.
    公开号:US20090143361A1
    公开(公告)日:2009-06-04
    The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders.
    这项发明涉及吡啶并[3,2-e]吡嗪化合物,涉及其制备方法,包括这些化合物的药物组成物以及这些化合物的药用,这些化合物是磷酸二酯酶10的抑制剂,作为治疗中枢神经系统疾病、肥胖和代谢紊乱的活性化合物。
  • [EN] PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10<br/>[FR] PYRIDO[3,2-E]PYRAZINES, LEUR PROCÉDÉ DE PRÉPARATION, ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE 10
    申请人:WYETH CORP
    公开号:WO2009070583A1
    公开(公告)日:2009-06-04
    The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders.
查看更多

同类化合物

顺式-3-(8-氨基-1-溴咪唑并[1,5-a]吡嗪-3-基)-1-甲基环丁醇 咪唑并[1,5-a]吡嗪-8-胺 咪唑并[1,5-a]吡嗪-8(7H)-硫酮 咪唑并[1,5-a]吡嗪-3-硫醇 N-(2,6-二甲基苯基)-5-(4-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 N-(2,6-二甲基苯基)-5-(3-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 8-氯咪唑并[1,5-a]吡嗪 8-氯咪唑并[1,5-A]吡嗪-1-甲酸乙酯 8-氯-3-环丁基-1-碘-咪唑并[1,5-a]吡嗪 8-氯-3-异丙基咪唑并[1,5-A]吡嗪 8-氯-1-碘-3-异丙基咪唑并[1,5-A]吡嗪 6-氯咪唑并[1,5-A]吡嗪 5H,10H-二咪唑并[1,5-a:1, 5-d] 吡嗪-5,10-二酮 5-溴-8-氯咪唑并[1,5-a]吡嗪 5-溴-7-(4-甲氧基苄基)咪唑并[1,5-a]吡嗪-8-(7H)-酮 5-(4-甲氧基苯基)-7H-咪唑并[1,5-a]吡嗪-8-酮 5,10-二氧代-5H,10H-二咪唑并[1,5-a:1',5'-d]吡嗪-1,6-二甲酸 3-甲基咪唑并[1,5-a]吡嗪-8(7H)-硫酮 3-甲基咪唑并[1,5-A]吡嗪 3-环己基咪唑并[1,5-a]吡嗪 3-环丁基-1-碘-咪唑并[1,5-a]吡嗪-8-胺 3-(甲硫基)-1-硝基-咪唑并[1,5-a]吡嗪 3-(甲氧基甲基)-咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯-1-碘咪唑并[1,5-a]吡嗪 3-(三氟甲基)咪唑并[1,5-a]吡嗪 3-(8-BROMO-1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 3-(1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 1-碘-3-异丙基咪唑并[1,5-A]吡嗪-8-胺 1-碘-3-叔丁基咪唑并[1,5-a]吡嗪-8-胺 1-溴-6-氯-咪唑并[1,5-a]吡嗪 1-溴-3-甲基-咪唑并[1,5-a]吡嗪 1-溴-3-(四氢-2H-吡喃-4-基)咪唑并[1,5-a]吡嗪-8-胺 mesityl(8-methoxy-3-methylimidazo[1,5-a]pyrazin-5-yl)methanol 3-ethylsulfanyl-7H-imidazo[1,5-a]pyrazin-8-one;hydrochloride (cis)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)cyclohexyl acetate trans-[Ni(mcpa)2(H2O)2] 3-(8-amino-1-iodoimidazo[1,5-a]pyrazin-3-yl)-N-ethyl-N-(2-hydroxyethyl)propanamide 8-amino-3-cyclopropylimidazo[1,5-a]pyrazine-1-carboxylic acid 3-(8-amino-1-iodoimidazo[1,5-a]pyrazin-3-yl)cyclobutanol 2,3-Diamino-5-iodo-3H-pyrimidin-4-one Cyclobutanol, 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)-1-methyl-, cis- 1-iodo-3-[3-(4-methyl-piperazin-1-yl)-cyclobutyl]-imidazo[1,5-a]pyrazin-8-ylamine 1-(2-phenylethyl)-6-cyanomethyl-7,8-dibromopyrrolo[1,2-a]pyrazine N-(1-methylethyl)-2-[6-[3-(methyloxy)phenyl]-4-oxo-2-{[3-(1-piperidinyl)propyl]oxy}pyrazolo[1,5-a]pyrazin-5(4H)-yl]acetamide dibromobis(2,5-dimethylpyrazine)zinc(II) N-(((trans)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)cyclohexyl)methyl)acetamide 5-chloro-1-iodo-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazin-8-amine methyl (5R,6R,7S,8S)-8-acetamido-6,7-bis(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-acetate methyl ((trans)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)cyclohexyl)methylcarbamate